Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy.
Oleksandr Valentynovych OliynykWojciech BargAnna SlifirczykYanina OliynykSerhij DubrovVitaliy GurianovMarta RoratPublished in: Life (Basel, Switzerland) (2021)
The use of unfractionated heparin in the treatment of COVID-19-associated coagulopathy seems to be more effective at reducing the risk of intubation and death than enoxaparin at prophylactic doses.